Latest Breaking News On - Committee for orphan medicinal products - Page 5 : comparemela.com
Positive opinion from Committee for Medicinal Products for Human Use recommending approval of Bylvay® (odevixibat) based on Phase III ASSERT clinical-trial data in Alagille syndrome (ALGS) already received in July 2023Committee for Orphan Medicinal Products confirms a negative opinion of its review recommending not to maintain the orphan designation for Bylvay in ALGSIpsen plans to submit a new Marketing Authorisation Application for the treatment of ALGS by the end of 2023 under a new brand nam
ShanghaiChinaUnited-statesParisFrance-generalFranceSaclayItalyCambridgeCambridgeshireUnited-kingdomGermany